Xu GG - Search Results

1

Xu GG, Etzkorn FA. Xu GG, et al. Drug News Perspect. 2009 Sep;22(7):399-407. doi: 10.1358/dnp.2009.22.7.1381751. Drug News Perspect. 2009. PMID: 19890497 Free article. Review.

2

Convergent synthesis of alpha-ketoamide inhibitors of Pin1.

Xu GG, Etzkorn FA. Xu GG, et al. Org Lett. 2010 Feb 19;12(4):696-9. doi: 10.1021/ol9027013. Org Lett. 2010. PMID: 20102178 Free PMC article.

3

A reduced-amide inhibitor of Pin1 binds in a conformation resembling a twisted-amide transition state.

Xu GG, Zhang Y, Mercedes-Camacho AY, Etzkorn FA. Xu GG, et al. Biochemistry. 2011 Nov 8;50(44):9545-50. doi: 10.1021/bi201055c. Epub 2011 Oct 18. Biochemistry. 2011. PMID: 21980916 Free PMC article.

4

Cyclohexyl ketone inhibitors of Pin1 dock in a trans-diaxial cyclohexane conformation.

Xu GG, Slebodnick C, Etzkorn FA. Xu GG, et al. PLoS One. 2012;7(9):e44226. doi: 10.1371/journal.pone.0044226. Epub 2012 Sep 19. PLoS One. 2012. PMID: 23028504 Free PMC article.

5

Kinetic isotope effects support the twisted amide mechanism of Pin1 peptidyl-prolyl isomerase.

Mercedes-Camacho AY, Mullins AB, Mason MD, Xu GG, Mahoney BJ, Wang X, Peng JW, Etzkorn FA. Mercedes-Camacho AY, et al. Among authors: xu gg. Biochemistry. 2013 Nov 5;52(44):7707-13. doi: 10.1021/bi400700b. Epub 2013 Oct 24. Biochemistry. 2013. PMID: 24116866 Free PMC article.

6

Exploration on natural product anibamine side chain modification toward development of novel CCR5 antagonists and potential anti-prostate cancer agents.

Xu GG, Zaidi SA, Zhang F, Singh S, Raborg TJ, Yuan Y, Zhang Y. Xu GG, et al. Bioorg Med Chem Lett. 2015 Sep 1;25(17):3721-5. doi: 10.1016/j.bmcl.2015.06.029. Epub 2015 Jun 15. Bioorg Med Chem Lett. 2015. PMID: 26096680

7

Carnitine palmitoyltransferase 1A functions to repress FoxO transcription factors to allow cell cycle progression in ovarian cancer.

Shao H, Mohamed EM, Xu GG, Waters M, Jing K, Ma Y, Zhang Y, Spiegel S, Idowu MO, Fang X. Shao H, et al. Among authors: xu gg. Oncotarget. 2016 Jan 26;7(4):3832-46. doi: 10.18632/oncotarget.6757. Oncotarget. 2016. PMID: 26716645 Free PMC article.

8

VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditions.

Abdulmalik O, Pagare PP, Huang B, Xu GG, Ghatge MS, Xu X, Chen Q, Anabaraonye N, Musayev FN, Omar AM, Venitz J, Zhang Y, Safo MK. Abdulmalik O, et al. Among authors: xu gg. Sci Rep. 2020 Nov 20;10(1):20277. doi: 10.1038/s41598-020-77171-2. Sci Rep. 2020. PMID: 33219275 Free PMC article.

9

Nanoconjugated NAP as a Potent and Periphery Selective Mu Opioid Receptor Modulator To Treat Opioid-Induced Constipation.

Xu GG, Zolotarskaya OY, Williams DA, Yuan Y, Selley DE, Dewey WL, Akbarali HI, Yang H, Zhang Y. Xu GG, et al. ACS Med Chem Lett. 2016 Nov 21;8(1):78-83. doi: 10.1021/acsmedchemlett.6b00382. eCollection 2017 Jan 12. ACS Med Chem Lett. 2016. PMID: 28105279 Free PMC article.

10

Design, Synthesis, and Biological Evaluation of Ester and Ether Derivatives of Antisickling Agent 5-HMF for the Treatment of Sickle Cell Disease.

Xu GG, Pagare PP, Ghatge MS, Safo RP, Gazi A, Chen Q, David T, Alabbas AB, Musayev FN, Venitz J, Zhang Y, Safo MK, Abdulmalik O. Xu GG, et al. Mol Pharm. 2017 Oct 2;14(10):3499-3511. doi: 10.1021/acs.molpharmaceut.7b00553. Epub 2017 Sep 13. Mol Pharm. 2017. PMID: 28858508 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

53 results

Search Page

Filters